Avant Brands Terminates Trademark Licensing Agreement with Adjupharm
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 17 2026
0mins
Should l Buy IMCC?
Avant Brands' wholly-owned subsidiary, GreenTec Holdings, has issued a formal notice of termination for its Trademark Licensing Agreement with Adjupharm, a subsidiary of IM Cannabis Corp. The Agreement was originally announced on May 1, 2024.The decision comes as Avant initiates a broader strategic transition to optimize its international distribution channels and ensure its partnerships are fully synchronized with the Company's long-term global growth strategy. Effective May 31, 2026, all trademark and distribution rights for the blk mkt brand in Germany and Switzerland will revert to GreenTec. Germany represents Avant's largest international export market, as reported in the Company's Fiscal 2025 results. Following the formal termination notice, Avant has initiated an official process to identify a partner capable of maximizing the Company's established momentum in Germany. The Company is vetting established distributors and operators based on market leadership, fiscal & operational maturity and strategic infrastructure.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IMCC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IMCC
About IMCC
IM Cannabis Corp. is an international cannabis company that provides cannabis products to medical patients in Israel and Germany. The Company's ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of its products throughout the entire value chain. In Germany, the Company’s ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. The Company's brands include The Craft Collection, The Top-Shelf Collection, The Signature Collection, The Full Spectrum Extracts, Roma, The WAGNERS, BLKMKT, LOT420, The PICO collection, and Flower.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IM Cannabis Receives Nasdaq Compliance Notice
- Compliance Notice: IM Cannabis has received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement, needing to regain compliance by October 6, 2026, by maintaining a closing bid price of at least $1.00 for 10 consecutive trading days, highlighting the compliance pressure the company faces.
- Time Constraint: The company has 180 days to meet this requirement, and although the current share price is $0.3609, up 1.66% from the previous trading day, it remains significantly below the compliance threshold, which may affect investor confidence.
- Trading Impact: IM Cannabis stated that the notice has no immediate impact on its Nasdaq listing or trading, allowing its shares to continue trading on the Nasdaq Capital Market, providing the company with a buffer to regain compliance.
- Market Reaction: Despite facing compliance challenges, IM Cannabis's stock price saw a slight increase following the announcement, reflecting a cautiously optimistic market sentiment regarding the company's ability to restore compliance, which could influence its financing and market image.
See More
IM Cannabis Receives Nasdaq Compliance Notice
- Compliance Notice: IM Cannabis Corp. has received a written notice from Nasdaq indicating that its stock price has fallen below the minimum requirement of $1.00 per share, necessitating compliance within 180 days to avoid delisting risks.
- Regaining Compliance Deadline: The company has until October 6, 2026, to regain compliance, and if the stock price meets the requirement for ten consecutive trading days during this period, it will receive written confirmation of compliance, thus avoiding delisting.
- Subsequent Compliance Opportunity: If compliance is not achieved within the initial 180 days, the company may apply for an additional 180-day compliance period, provided it meets other listing standards, indicating its commitment to maintaining its Nasdaq listing.
- Market Monitoring Strategy: IM Cannabis intends to closely monitor its stock price and consider measures during the compliance period to regain compliance, ensuring its continued listing status on Nasdaq.
See More
IM Cannabis Receives Nasdaq Compliance Notice
- Compliance Notice: IM Cannabis Corp. has received a written notice from Nasdaq indicating non-compliance with the minimum bid price requirement of $1.00 per share, necessitating compliance within 180 days to avoid delisting risks.
- Grace Period Arrangement: The company has until October 6, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive trading days, with the possibility of an additional 180-day grace period if necessary.
- Market Impact: Although the notice does not immediately affect the company's Nasdaq listing or trading, ongoing compliance pressure may undermine investor confidence, potentially impacting stock performance negatively.
- Strategic Response: The company intends to closely monitor its stock price and consider necessary actions to regain compliance, demonstrating its commitment to maintaining its Nasdaq listing and enhancing shareholder value.
See More
IM Cannabis Reports FY Revenue of C$54.7M
- Annual Revenue Performance: IM Cannabis reported a fiscal year revenue of C$54.7 million, demonstrating resilience in the face of market challenges, which reflects the company's potential for growth despite adversity.
- Gross Profit Increase: The company's gross profit rose approximately 15% year-over-year to C$9.686 million, primarily driven by enhanced cost efficiencies and optimized supply chains, laying a solid foundation for future profitability.
- Market Performance Volatility: Despite the improved financial metrics, IMCC shares fell by 6.8%, indicating market concerns regarding the company's future growth, which could impact investor confidence.
- Contribution from German Market: The higher-margin sales in Germany significantly boosted overall performance, indicating that the company's international expansion strategy is gradually yielding results, with potential for further diversification of revenue streams in the future.
See More
IM Cannabis to Acquire 51% of Blackaxe Technologies
- Strategic Expansion Opportunity: IM Cannabis (IMCC) has signed a letter of intent to acquire 51% of Polish company Blackaxe Technologies, marking a potential entry into the defense and homeland security technology sectors, thereby enhancing its market competitiveness.
- Integration of Technical Expertise: Blackaxe specializes in advanced defense and intelligence solutions, and the acquisition will help IMCC integrate this technical expertise, thereby improving its capabilities and product offerings in related industries.
- Positive Market Reaction: Following the acquisition announcement, IMCC's stock rose 13.16% in premarket trading to $0.8955 per share, indicating investor optimism regarding the transaction.
- Future Growth Potential: By entering the defense and security technology market, IMCC not only diversifies its business model but also capitalizes on the growth potential in this sector, further driving its long-term strategic development.
See More
IM Cannabis to Acquire 51% Stake in Blackaxe Technologies
- Strategic Expansion: IM Cannabis Corp. has announced a non-binding letter of intent to acquire 51% of Blackaxe Technologies, marking a strategic move into the defense and security technology sectors, which is expected to enhance its market competitiveness.
- Growing Market Demand: The global defense and security market is rapidly expanding due to rising geopolitical tensions, and IMC's acquisition will enable it to leverage Blackaxe's advanced capabilities in satellite intelligence and counter-drone technologies to meet increasing market demands.
- Technological Integration Advantage: Blackaxe specializes in defense solutions based on advanced Israeli technologies, and IMC's acquisition will allow it to integrate these technologies, enhancing its business diversification and innovation capabilities beyond the medical cannabis sector.
- Transaction Conditions and Risks: The deal is subject to due diligence and regulatory approvals, and IMC faces multiple risks including industry regulations and market competition; successfully completing the transaction will have significant implications for its future growth.
See More
IM Cannabis Receives Nasdaq Compliance Notice
- Compliance Notice: IM Cannabis has received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement, needing to regain compliance by October 6, 2026, by maintaining a closing bid price of at least $1.00 for 10 consecutive trading days, highlighting the compliance pressure the company faces.
- Time Constraint: The company has 180 days to meet this requirement, and although the current share price is $0.3609, up 1.66% from the previous trading day, it remains significantly below the compliance threshold, which may affect investor confidence.
- Trading Impact: IM Cannabis stated that the notice has no immediate impact on its Nasdaq listing or trading, allowing its shares to continue trading on the Nasdaq Capital Market, providing the company with a buffer to regain compliance.
- Market Reaction: Despite facing compliance challenges, IM Cannabis's stock price saw a slight increase following the announcement, reflecting a cautiously optimistic market sentiment regarding the company's ability to restore compliance, which could influence its financing and market image.
See More
IM Cannabis Receives Nasdaq Compliance Notice
- Compliance Notice: IM Cannabis Corp. has received a written notice from Nasdaq indicating that its stock price has fallen below the minimum requirement of $1.00 per share, necessitating compliance within 180 days to avoid delisting risks.
- Regaining Compliance Deadline: The company has until October 6, 2026, to regain compliance, and if the stock price meets the requirement for ten consecutive trading days during this period, it will receive written confirmation of compliance, thus avoiding delisting.
- Subsequent Compliance Opportunity: If compliance is not achieved within the initial 180 days, the company may apply for an additional 180-day compliance period, provided it meets other listing standards, indicating its commitment to maintaining its Nasdaq listing.
- Market Monitoring Strategy: IM Cannabis intends to closely monitor its stock price and consider measures during the compliance period to regain compliance, ensuring its continued listing status on Nasdaq.
See More
IM Cannabis Receives Nasdaq Compliance Notice
- Compliance Notice: IM Cannabis Corp. has received a written notice from Nasdaq indicating non-compliance with the minimum bid price requirement of $1.00 per share, necessitating compliance within 180 days to avoid delisting risks.
- Grace Period Arrangement: The company has until October 6, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive trading days, with the possibility of an additional 180-day grace period if necessary.
- Market Impact: Although the notice does not immediately affect the company's Nasdaq listing or trading, ongoing compliance pressure may undermine investor confidence, potentially impacting stock performance negatively.
- Strategic Response: The company intends to closely monitor its stock price and consider necessary actions to regain compliance, demonstrating its commitment to maintaining its Nasdaq listing and enhancing shareholder value.
See More
IM Cannabis Reports FY Revenue of C$54.7M
- Annual Revenue Performance: IM Cannabis reported a fiscal year revenue of C$54.7 million, demonstrating resilience in the face of market challenges, which reflects the company's potential for growth despite adversity.
- Gross Profit Increase: The company's gross profit rose approximately 15% year-over-year to C$9.686 million, primarily driven by enhanced cost efficiencies and optimized supply chains, laying a solid foundation for future profitability.
- Market Performance Volatility: Despite the improved financial metrics, IMCC shares fell by 6.8%, indicating market concerns regarding the company's future growth, which could impact investor confidence.
- Contribution from German Market: The higher-margin sales in Germany significantly boosted overall performance, indicating that the company's international expansion strategy is gradually yielding results, with potential for further diversification of revenue streams in the future.
See More
IM Cannabis to Acquire 51% of Blackaxe Technologies
- Strategic Expansion Opportunity: IM Cannabis (IMCC) has signed a letter of intent to acquire 51% of Polish company Blackaxe Technologies, marking a potential entry into the defense and homeland security technology sectors, thereby enhancing its market competitiveness.
- Integration of Technical Expertise: Blackaxe specializes in advanced defense and intelligence solutions, and the acquisition will help IMCC integrate this technical expertise, thereby improving its capabilities and product offerings in related industries.
- Positive Market Reaction: Following the acquisition announcement, IMCC's stock rose 13.16% in premarket trading to $0.8955 per share, indicating investor optimism regarding the transaction.
- Future Growth Potential: By entering the defense and security technology market, IMCC not only diversifies its business model but also capitalizes on the growth potential in this sector, further driving its long-term strategic development.
See More
IM Cannabis to Acquire 51% Stake in Blackaxe Technologies
- Strategic Expansion: IM Cannabis Corp. has announced a non-binding letter of intent to acquire 51% of Blackaxe Technologies, marking a strategic move into the defense and security technology sectors, which is expected to enhance its market competitiveness.
- Growing Market Demand: The global defense and security market is rapidly expanding due to rising geopolitical tensions, and IMC's acquisition will enable it to leverage Blackaxe's advanced capabilities in satellite intelligence and counter-drone technologies to meet increasing market demands.
- Technological Integration Advantage: Blackaxe specializes in defense solutions based on advanced Israeli technologies, and IMC's acquisition will allow it to integrate these technologies, enhancing its business diversification and innovation capabilities beyond the medical cannabis sector.
- Transaction Conditions and Risks: The deal is subject to due diligence and regulatory approvals, and IMC faces multiple risks including industry regulations and market competition; successfully completing the transaction will have significant implications for its future growth.
See More
